Dissertations / Theses on the topic 'Hormone therapy'
To see the other types of publications on this topic, follow the link: Hormone therapy.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Hormone therapy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
1
陳蒓 and Tzun Rachel Chan. "Growth hormone therapy for growth hormone deficiency." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2001. http://hub.hku.hk/bib/B31970308.
Full text
2
Chan, Tzun Rachel. "Growth hormone therapy for growth hormone deficiency." Hong Kong : University of Hong Kong, 2001. http://sunzi.lib.hku.hk/hkuto/record.jsp?B22926288.
Full text
3
Coo, Helen. "Knowledge of hormone therapy and its impact on adherence to hormone therapy for prevention." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape8/PQDD_0003/MQ42601.pdf.
Full text
4
Habiba, Marwan A. "Endometrial responses to hormone replacement therapy." Thesis, University of Leicester, 1998. http://hdl.handle.net/2381/30471.
Full text
5
Ödmark, Inga-Stina. "Hormone replacement therapy : benefits and adverse effects." Doctoral thesis, Umeå universitet, Obstetrik och gynekologi, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-243.
Full textAbstract:
Background: Numerous studies have shown that estrogen replacement therapy (ERT) is an effective treatment for vasomotor symptoms, insomnia and vaginal dryness. Beneficial effects have also been shown on lipid patterns and on the incidence of osteoporotic fractures. As ERT increases the risk of endometrial adenocarcinoma, combinations with various progestogens have been developed in order to protect the endometrium. However, the addition of progestogens tends to reduce the beneficial effects of estrogens on mood, cognition and lipid metabolism. The added progestogen often causes side effects such as irritability and depression. There is evidence that the effect on wellbeing varies between women and with the type of progestogen used. Women who prefer to avoid withdrawal bleedings can be given continuous combined hormone replacement therapy (HRT). Unfortunately, irregular bleedings are common at the beginning of treatment and reduces compliance. Recently, several studies have reported an increased risk of breast cancer and venous thrombosis, and therefore long-term treatment with HRT for women without climacteric symptoms is no longer recommended. The ongoing debate has, for the time being, resulted in a recommendation that improving quality of life (QoL) by treatment of climacteric symptoms should be the only indication for prescribing HRT. Aims and methods: The aims of the study were to investigate bleeding patterns, changes in wellbeing at onset and during long-term treatment, and lipid and lipoprotein profiles with two different types of continuous combined HRT. In addition, women starting, and women switching from mainly sequential HRT were compared. The design was a randomised, double-blind, one year, prospective, multicentre study including 249 healthy postmenopausal women who were given continuous daily oral treatment with either combined 0.625mg conjugated estrogen (CE) and 5mg medroxyprogesterone acetate (MPA) or combined 2mg 17β - estradiol (E2) and 1mg norethisterone acetate (NETA). Bleedings, if any, were recorded daily throughout the study. The main outcome measures (changes in wellbeing and climacteric symptoms) consisted of daily ratings of 12 items on a validated symptom scale. Serum concentrations of lipids and lipoproteins were measured at baseline and after one year of treatment. Results and conclusions: The majority of drop-outs were confined to the first three months, and the main reasons were bleedings and/or decreased wellbeing. Drop-outs were three times more common in the E2/NETA group. During the first month, 67% of the women reported irregular bleedings. The number of bleeding days decreased on both treatments during the first four months. Treatment with CE/MPA resulted in less irregular bleedings and a shorter time to amenorrhoea compared to E2/NETA. As expected, "starters" experienced more sweats than "switchers" at the onset of treatment, but both groups improved significantly. Side effects such as breast tenderness, swelling, depression and irritability appeared during the first treatment week in both groups. The side effects of HRT appeared much more quickly than the benefits and were more frequent in women with a history of premenstrual syndrome (PMS). Breast tenderness was more common in the E2/NETA group throughout the whole study period. Apart from that, there were no differences between the two treatment regimens as regards effects on well-being at the end of the study. Lipoprotein(a) levels, an important risk factor for cardiovascular disease, decreased in both treatment groups. Triglyceride levels increased in women treated with CE/MPA, and levels of total cholesterol, high density lipoprotein and low density lipoprotein fell in the E2/NETA group. In conclusion, treatment with E2/NETA caused more bleeding problems than treatment with CE/MPA. CE/MPA was better tolerated than E2/NETA at the beginning of the study, but among the women remaining in the study there was no difference in QoL between the two treatment groups. HRT counselling should take into account that a history of PMS increases the likelihood of side effects and that these may precede any beneficial effects. Both treatments produced beneficial effects on lipid and lipoprotein levels, and neither of the regimens was superior in this respect.
6
Lundström, Eva. "Mammographic breast density and postmenopausal hormone therapy /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-581-X/.
Full text
7
Ödmark, Inga-Stina. "Hormone replacement therapy : benefits and adverse effects /." Umeå : Univ, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-243.
Full text
8
Björn, Inger. "Hormone replacement therapy and effects on mood." Doctoral thesis, Umeå universitet, Obstetrik och gynekologi, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-94115.
Full textAbstract:
Background: During the past 5 decades, hormone replacement therapy (HRT) has been used, and appreciated for its beneficial effects, by millions of women in their menopause. As treatment for climacteric symptoms, estrogen is outstanding, and effects on hot flushes, vaginal dryness, and insomnia have been widely documented. The increased risks of venous thrombosis and breast cancer, however, restrict the use of estrogen. Estrogen treatment in women with a remaining uterus includes a progestin, added to protect the endometrium from hyperplasia and malignancies. The long-standing clinical impression, that progestin addition negatively influences mood, has been discussed in previous studies. Mood deterioration is, however, not mortal, although mood is important to the wellbeing and daily functioning of women treated with hormones. Studies of the mental side effects of HRT add to our understanding of steroid effects in the brain. Aims and methods: In our studies, we aimed to establish to what extent negative side effects cause women to discontinue HRT, and find out which drug compounds lead to mood deterioration. The questions asked were whether the type and dose of progestin and the estrogen dose during the progestin addition influence the mood and physical symptoms during sequential HRT. Compliance with HRT and reasons for discontinuing the therapy were evaluated in a retrospective longitudinal follow-up study. Treatment effects were studied in three randomized, double-blind, cross-over trials. During continuous estrogen treatment, effects of sequential addition of a progestin were studied by comparing two different progestins, medroxyprogesterone acetate (MPA) andnorethisterone acetate (NETA), comparing different doses of the same progestin, MPA, and comparing two doses of estrogen during addition of the same dose of MPA. The main outcome measure was the daily rating on mood and physical symptoms kept by the participants throughout the studies. The clinical trials were carried out at three gynecological centers in northern Sweden. Results and conclusions: Besides fear of cancer and a wish to determine whether climacteric symptoms had meanwhile disappeared, negative side effects was the most common reason or discontinuing HRT. Tension in the breasts, weight gain, a depressed mood, abdominal bloating, and irritability were the most important side effects seen both in women who continued HRT and in women who had discontinued the therapy. In our clinical trials, we showed that addition of a progestin to estrogen treatment induces cyclic mood swings characterized by tension, irritability, and depression, as well as increased breast tension, bloatedness, and hot flushes. Women with a history of premenstrual syndrome (PMS) appeared to be more sensitive to the progestin addition and responded with lower mood scores compared with women without previous PMS. In our studies, MPA provoked depressed mood to a lesser extent than did NETA. Surprisingly, the higher dose of MPA (20 mg) enhanced the mood, compared with 10 mg, when added to estrogen treatment. In women continuously treated with 3 mg estradiol, mood and physical symptoms worsened during the progestin addition, as compared with treatment with 2 mg estradiol. The negative side effects seen during sequential HRT have much in common with symptoms seen in the premenstrual dysphoric disorder (PMDD), which is a psychoneuroendocrine disorder with psychiatric expression. Explanations for treatment effects on mood are likely to be found in drug interactions with neurotransmitter systems of the brain.Diss. (sammanfattning) Umeå : Umeå universitet, 2003
digitalisering@umu
9
Homer, Natalie. "Erythocyte oxidative stress : focus on hormone replacement therapy." Thesis, University of Strathclyde, 2003. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.273852.
Full text
10
Khorsheed, Sarah. "Kartläggning av användningsmönstret av Menopausal Hormone Therapy (MHT)." Thesis, Uppsala universitet, Institutionen för farmaci, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-432290.
Full textAbstract:
Background Menopausal hormone therapy (MHT) is used to treat menopausal symptoms. The use of MHT decreased after the Women's Health Initiative (WHI) study which proved an increased risk of stroke and breast cancer. In 2019 the Swedish Medical Products Agency was commissioned to update the treatment recommendations of MHT. Aim To conduct a review of studies analyzing the use of MHT through the literature, and to describe the use of MHT in Sweden. Methods A literature study assessing published studies on MHT use from different countries, by using PubMed database and publications found at various Swedish authorities’ websites such as the Swedish Medical Products Agency and the National Board of Health and Welfare between 2003 and 2020 that fulfilled the purpose.A register study to analyze MHT use in the Swedish female population between 2008 – 2019 for women between 40 – 59 years. The databases used was the National Board of Health and Welfare's patient register and the Swedish Prescribed Drug Register Results There is a large variation in MHT utilization between countries due to differences in guidelines and other factors.In Sweden, the use of MHT was low in comparison with other countries, women had more knowledge about the treatment and prescribers followed the Swedish Medical Products Agency's recommendations.In 2019, the increase in patients diagnosed with menopause was twice as high as it was in 2008. in addition, the use of (MHT) in Sweden increased in the period 2017 - 2020. The most widely used MHT group was estrogen. Conclusions MHT use has increased in the Swedish population between 2017 and 2020, further knowledge of the benefit- risk profile is needed
11
Fischer, Mary A. "Women’s Experiences of Discontinuing Hormone Therapy: A Dissertation." eScholarship@UMMS, 2011. https://escholarship.umassmed.edu/gsn_diss/23.
Full textAbstract:
Although many women find relief from menopause through hormone therapy (HT), current guidelines recommend that HT be used only for short-term relief of symptoms. Women who attempt to stop HT often encounter troublesome recurrent symptoms leading to a diminished quality of life (QoL); 25% of women who discontinue eventually resume HT. Unfortunately, there is little information for women and their health care providers as to the best way to discontinue HT or how to prepare and guide women through this process. An in-depth description of women‘s experiences during HT discontinuation and the factors influencing recurrent symptoms, QoL and discontinuation outcome would provide knowledge to develop much needed counseling and support interventions. The purpose of this study was to explore women‘s experiences discontinuing hormone therapy for menopause.
This Internet-based mixed-methods study used a dominant Qualitative Descriptive design with embedded quantitative QoL measurements. Participants completed the quantitative questionnaires online while open-ended questions were completed either online or by telephone. Interview data were analyzed through Qualitative Content Analysis; descriptive statistics were used to explore the quantitative measures. Participants were stratified by discontinuation status for comparison of variations in discontinuation experiences, QoL and influencing factors.
Thirty-four women (20 stopped, 9 resumed, 4 tapering) were enrolled. One overarching theme--'a solitary journey'--emerged: although all women embarked on this journey, each woman traveled her own path. Two subthemes--'burden and interference' and 'appraising risk'--encompassed the symptom factors (severity, interference and sensitivity) that influenced women's experiences and the manner in which women evaluated their options. Other influencing factors included: readiness viii and reasons for stopping HT, beliefs about menopause and roles. QoL was strongly connected to symptoms for many but not all women. Information from health care providers was inconsistent; women desired more support from providers and other women.
The rich description of women's experiences stopping HT highlights the need for providers to assess women's sensitivity to symptoms and readiness to discontinue to determine which women might benefit from more support. Greater health literacy would enhance women's understanding of HT risks. More research is needed on symptom clusters and interference and strategies for minimizing their impact.
12
Roberts, April M. "Steroid hormone treatments alter growth characteristics in transformed human ovarian cell lines." Virtual Press, 2003. http://liblink.bsu.edu/uhtbin/catkey/1265095.
Full text
13
Thomas, Chandra Mary. "Current use of hormone therapy and screening mammography outcomes." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0019/MQ49658.pdf.
Full text
14
Daly, Edel. "Balancing the benefits and risks of hormone replacement therapy." Thesis, University of Oxford, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.393609.
Full text
15
Griffiths, Frances Ellen. "Hormone replacement therapy : perspectives from women, medicine and sociology." Thesis, Durham University, 1997. http://etheses.dur.ac.uk/5084/.
Full textAbstract:
Developed on the boundary between medicine and sociology, this thesis develops a critique of the perspectives of these disciplines through analysis of a study of women's perspectives on hormone replacement therapy. Women's perspectives are explored through a postal questionnaire survey and a study using individual interviews and focus groups. The survey results provide a measure of women’s attitudes towards, and knowledge of, hormone replacement therapy. The individual interviews detail the way women move towards a decision about the therapy and identifies common themes, particularly women's fears and what influences their fears. The focus groups explore contrasting themes including women's control and choice in decisions about therapy, contrary themes in women’s attitudes and the different ways of thinking used by the women. The results of the studies are assessed for their implications for clinical general practice. The thesis also takes a sociological perspective on women and HRT and on the research process, in particular exploring two themes. Firstly, the interaction between the social context, the research subject and the research process. This includes the social factors influencing the development of the research and choice of research methods, and the influence of the research methods on the results obtained. The second theme is the perspectives and levels of analysis used by the main disciplines contributing to the thesis; biomedicine, biostatistics, general practice and sociology. The thesis explores how the different perspectives and levels of analysis influence research and how they are used to manage the social context. These explorations are used to suggest future directions for research on hormone replacement therapy and for general practice.
16
Jagger, J. P. "Endocrine responses to gonadotrophin releasing hormone therapy in cattle." Thesis, University of Nottingham, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.376393.
Full text
17
Thompson, Jennifer Jo, Cheryl Ritenbaugh, and Mark Nichter. "Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making." BIOMED CENTRAL LTD, 2017. http://hdl.handle.net/10150/626039.
Full textAbstract:
Background: In recent years, compounded bioidentical hormone therapy (CBHT) has emerged as a popular alternative to manufactured, FDA approved hormone therapy (HT)-despite concerns within the medical community and the availability of new FDA approved "bioidentical" products. This study aims to characterize the motivations for using CBHT in a U.S. sample of ordinary midlife women. Methods: We analyze data collected from 21 current and former users of CBHT who participated in a larger qualitative study of menopausal decision-making among U.S. women. Interviews and focus groups were audio-recorded, transcribed verbatim, and analyzed thematically using an iterative inductive and deductive process. Results: Although women's individual motivations varied, two overarching themes emerged: "push motivations" that drove women away from conventional HT and from alternative therapies, and "pull motivations" that attracted women to CBHT. Push motivations focused on (1) fear and uncertainty about the safety of conventional HT, (2) an aversion to conjugated estrogens in particular, and (3) and overarching distrust of a medical system perceived as dismissive of their concerns and overly reliant on pharmaceuticals. Participants also voiced dissatisfaction with the effectiveness of herbal and soy supplements. Participants were attracted to CBHT because they perceive it to be (1) effective in managing menopausal symptoms, (2) safer than conventional HT, (3) tailored to their individual bodies and needs, and (4) accompanied by enhanced clinical care and attention. Conclusions: This study finds that women draw upon a range of "push" and "pull" motivations in their decision to use CBHT. Importantly, we find that women are not only seeking alternatives to conventional pharmaceuticals, but alternatives to conventional care where their menopausal experience is solicited, their treatment goals are heard, and they are engaged as agents in managing their own menopause. The significance of this finding goes beyond understanding why women choose CBHT. Women making menopause treatment decisions of all kinds would benefit from greater shared decision-making in the clinical context in which they are explicitly invited to share their experiences, priorities, and preferences. This would also provide an opportunity for clinicians to discuss the pros and cons of conventional HT, CBHT, and other approaches to managing menopause.
18
Buttros, Davi de Araújo Brito [UNESP]. "Avaliação dos fatores de risco para osteoporose em mulheres na pós-menopausa." Universidade Estadual Paulista (UNESP), 2011. http://hdl.handle.net/11449/93094.
Full textAbstract:
Made available in DSpace on 2014-06-11T19:26:18Z (GMT). No. of bitstreams: 0
Previous issue date: 2011-02-09Bitstream added on 2014-06-13T20:15:06Z : No. of bitstreams: 1
bruttos_dab_me_botfm.pdf: 462681 bytes, checksum: 038e3f95141da86625e1f48b217bffe6 (MD5)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Avaliar o perfil da densidade mineral óssea (DMO) e os fatores de risco associados à osteoporose na pós-menopausa. Realizou-se estudo clínico-transversal com 431 mulheres. Idade entre 40-75 anos, atendidas ambulatorialmente em Hospital Universitário. Incluíram-se mulheres com: amenorréia>12 meses e idade ≥45 anos ou, ooforectomia ≥40 anos, com valores de DMO (coluna lombar e colo de fêmur) pelo DEXA dos últimos 12 meses. Fatores de risco avaliados: idade, idade e tempo de menopausa, tabagismo, atividade física (30min/5x/sem), artrite reumatóide (AR), uso de corticoterapia e de terapia hormonal (TH), fratura prévia, fratura materna de quadril e índice de massa corpórea (IMC=peso/altura2). Valores séricos de cálcio, fosfatase alcalina (FA) e calciúria-24h foram analisados. Empregou-se teste do Qui-quadrado (variáveis categóricas) e método de regressão logística no risco (odds ratio-OR) para osteoporose. A média de idade foi 54,1 ± 6,9 anos, tempo de menopausa 7,5 ± 5,8 anos, IMC 28,2 ± 5,3kg/m2. Encontrou-se: usuárias de TH 35,9%, exercício regular 27,3%, tabagistas 23,8%, menopausa <40anos 18,1%, fratura prévia 11,8%, fratura materna de quadril 10,7%, corticoterapia 4,8%, AR 4,0%. Pelos critérios da OMS, 106 (24,6%) mulheres apresentavam osteoporose (T-escore≤-2,5DP), 188 (43,6%) osteopenia (-1,0/-2,4DP) e 137 (31,8%) eram normais (≥-1,0DP). Detectou-se osteoporose em 12% das mulheres com idade entre 40-49anos, 21,8% 50-59 anos e 45,7% >60 anos (p<0,001). Osteoporose ocorreu em 11,8% com tempo de menopausa <5anos, 29,4% de 6-10anos, e 41% >10anos (p<0,001). Naquelas com menopausa precoce, 80% apresentaram osteopenia/osteoporose (p=0,032) e com IMC<20kg/m2, 50% osteoporóticas (p<0,001). Nenhuma associação foi observada entre DMO e valores de cálcio (p=0,174), FA (p=0,901) e calciúria (p=0,759). O risco de detectar osteoporose aumentou com idade...
To evaluate bone mineral density (BMD) profiles and their risk factors associated with postmenopausal osteoporosis. A cross-sectional clinical study was performed on 431 women aged 40-75 years and cared for at the outpatient clinic of a University Hospital. Women showing the following characteristics were included: amenorrhea >12 months and age ≥ 45 years or, ooforectomy ≥ 40 years with BMD values (lumbar spine and femur neck) by DXA of the last 12 months. Risk factors evaluated: age, age and time of menopause, smoking, physical activity (30min/5x/week), rheumatoid arthritis (RA), use of corticotherapy and hormone therapy (HT), previous fracture, maternal hip fracture and body mass index (BMI=weight/height2). Serum values of calcium, alkaline phosphatase (AP) and 24-h urinary calcium were analyzed. The Chi-square test was used for categorical variables, and the logistic regression method (odds ratio-OR) was utilized for osteoporosis risk. Mean age was 54.1±6.9 years, menopausal period 7.5±5.8 years, BMI 28.2±5.3 kg/m2. The following were found: HT users 35.9%; regular exercise 27.3%; smokers 23.8%; menopause < 40 years 18.1%; low calcium intake (<400mg/day) 55.3%; previous fracture 11.8%; maternal fracture 10.7%, corticotherapy 4.8%, RA 4.0%. According to WHO criteria, 106 (24.6%) women showed osteoporosis (T- score ≤ -2.5 DP), 188 (43.6%) osteopenia (-1.0/-2.4 DP), and 137 (31.8%) were normal (≥ -1.0 DP). Osteoporosis was detected in 12% of the women aged 40-49 years, 21.8% 50-59 years and 45.7% > 60 years (p<0.001). Osteoporosis occurred to 11.8% with a menopause period < 5 years, 29.4% from 6 to 10 years, and 41% > 10 years (p<0.001). Of the women with early menopause, 80% showed osteopenia/osteoporosis (p=0.032), and of those with BMI < 20kg/m2, 50% were osteoporotic (p<0.001). No association was observed between BMD and calcium values (p=0.174), AP (p=0.901)... (Complete abstract click electronic access below)
19
Riman, Tomas. "An epidemiologic study of epithelial ovarian malignancies : with a focus on hormone-related factors /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-362-7/.
Full text
20
Isaksson, Friman Erika. "Hormonal treatments and the breast : effects on sex steroid receptor expression and proliferation /." Stockholm : [Karolinska institutets bibl.], 2002. http://diss.kib.ki.se/2002/91-7349-182-9/.
Full text
21
Howe, Kathleen S. "Exercise therapy as treatment for postmenopausal osteoporosis in women not currently taking hormone replacement therapy." [Gainesville, Fla.] : University of Florida, 2004. http://purl.fcla.edu/fcla/etd/UFE0004600.
Full text
22
Armstrong, Alison L. "Hormone replacement therapy - effects on strength, balance and bone density." Thesis, University of Nottingham, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.284686.
Full text
23
Brooks, Alan Arnold. "Investigation of endometrial response to hormone therapy in oocyte recipients." Thesis, University College London (University of London), 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.362369.
Full text
24
Blackwelder, Reid B. "Use of Hormone Therapy for Menopausal Symptoms: A Shared Decision." Digital Commons @ East Tennessee State University, 2008. https://dc.etsu.edu/etsu-works/6911.
Full text
25
Basu, Reetobrata. "Growth Hormone Receptor in Melanoma: A Unique Approach to Therapy." Ohio University / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1470923234.
Full text
26
Towne, Cheryl Luann Rush. "Older women's beliefs about hormone replacement therapy : a qualitative study /." View online, 2000. http://repository.eiu.edu/theses/docs/32211130976791.pdf.
Full text
27
Wihlbäck, Anna-Carin. "Ovarian hormones and effects in the brain : studies of neurosteroid sensitivity, serotonin transporter and serotonin2A receptor binding in reproductive and postmenopausal women." Umeå : Univ, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-365.
Full text
28
Buttros, Davi de Araújo Brito. "Avaliação dos fatores de risco para osteoporose em mulheres na pós-menopausa /." Botucatu : [s.n.], 2011. http://hdl.handle.net/11449/93094.
Full textAbstract:
Resumo: Avaliar o perfil da densidade mineral óssea (DMO) e os fatores de risco associados à osteoporose na pós-menopausa. Realizou-se estudo clínico-transversal com 431 mulheres. Idade entre 40-75 anos, atendidas ambulatorialmente em Hospital Universitário. Incluíram-se mulheres com: amenorréia>12 meses e idade ≥45 anos ou, ooforectomia ≥40 anos, com valores de DMO (coluna lombar e colo de fêmur) pelo DEXA dos últimos 12 meses. Fatores de risco avaliados: idade, idade e tempo de menopausa, tabagismo, atividade física (30min/5x/sem), artrite reumatóide (AR), uso de corticoterapia e de terapia hormonal (TH), fratura prévia, fratura materna de quadril e índice de massa corpórea (IMC=peso/altura2). Valores séricos de cálcio, fosfatase alcalina (FA) e calciúria-24h foram analisados. Empregou-se teste do Qui-quadrado (variáveis categóricas) e método de regressão logística no risco (odds ratio-OR) para osteoporose. A média de idade foi 54,1 ± 6,9 anos, tempo de menopausa 7,5 ± 5,8 anos, IMC 28,2 ± 5,3kg/m2. Encontrou-se: usuárias de TH 35,9%, exercício regular 27,3%, tabagistas 23,8%, menopausa <40anos 18,1%, fratura prévia 11,8%, fratura materna de quadril 10,7%, corticoterapia 4,8%, AR 4,0%. Pelos critérios da OMS, 106 (24,6%) mulheres apresentavam osteoporose (T-escore≤-2,5DP), 188 (43,6%) osteopenia (-1,0/-2,4DP) e 137 (31,8%) eram normais (≥-1,0DP). Detectou-se osteoporose em 12% das mulheres com idade entre 40-49anos, 21,8% 50-59 anos e 45,7% >60 anos (p<0,001). Osteoporose ocorreu em 11,8% com tempo de menopausa <5anos, 29,4% de 6-10anos, e 41% >10anos (p<0,001). Naquelas com menopausa precoce, 80% apresentaram osteopenia/osteoporose (p=0,032) e com IMC<20kg/m2, 50% osteoporóticas (p<0,001). Nenhuma associação foi observada entre DMO e valores de cálcio (p=0,174), FA (p=0,901) e calciúria (p=0,759). O risco de detectar osteoporose aumentou com idade... (Resumo completo, clicar acesso eletrônico abaixo)Abstract: To evaluate bone mineral density (BMD) profiles and their risk factors associated with postmenopausal osteoporosis. A cross-sectional clinical study was performed on 431 women aged 40-75 years and cared for at the outpatient clinic of a University Hospital. Women showing the following characteristics were included: amenorrhea >12 months and age ≥ 45 years or, ooforectomy ≥ 40 years with BMD values (lumbar spine and femur neck) by DXA of the last 12 months. Risk factors evaluated: age, age and time of menopause, smoking, physical activity (30min/5x/week), rheumatoid arthritis (RA), use of corticotherapy and hormone therapy (HT), previous fracture, maternal hip fracture and body mass index (BMI=weight/height2). Serum values of calcium, alkaline phosphatase (AP) and 24-h urinary calcium were analyzed. The Chi-square test was used for categorical variables, and the logistic regression method (odds ratio-OR) was utilized for osteoporosis risk. Mean age was 54.1±6.9 years, menopausal period 7.5±5.8 years, BMI 28.2±5.3 kg/m2. The following were found: HT users 35.9%; regular exercise 27.3%; smokers 23.8%; menopause < 40 years 18.1%; low calcium intake (<400mg/day) 55.3%; previous fracture 11.8%; maternal fracture 10.7%, corticotherapy 4.8%, RA 4.0%. According to WHO criteria, 106 (24.6%) women showed osteoporosis (T- score ≤ -2.5 DP), 188 (43.6%) osteopenia (-1.0/-2.4 DP), and 137 (31.8%) were normal (≥ -1.0 DP). Osteoporosis was detected in 12% of the women aged 40-49 years, 21.8% 50-59 years and 45.7% > 60 years (p<0.001). Osteoporosis occurred to 11.8% with a menopause period < 5 years, 29.4% from 6 to 10 years, and 41% > 10 years (p<0.001). Of the women with early menopause, 80% showed osteopenia/osteoporosis (p=0.032), and of those with BMI < 20kg/m2, 50% were osteoporotic (p<0.001). No association was observed between BMD and calcium values (p=0.174), AP (p=0.901)... (Complete abstract click electronic access below)
Orientador: Jorge Nahás Neto
Coorientador: Eliana Aguiar Petri Nahás
Banca: Rogério Bonassi Machado
Banca: Adriana O. Pedro
Mestre
29
Ramaswami, Uma. "Hypochondroplasia : clinical and molecular spectrum and response to growth hormone therapy." Thesis, University College London (University of London), 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248138.
Full text
30
Wood, Elizabeth. "Women's decisions and decisional conflict regarding long term hormone replacement therapy." Thesis, University of Ottawa (Canada), 1995. http://hdl.handle.net/10393/9800.
Full textAbstract:
Long term preventive hormone replacement therapy (LTP-HRT) is attracting considerable attention for its potential in reducing the incidence of coronary heart disease and osteoporosis associated fractures in post-menopausal women. The study objectives were: (1) to describe women's decisions and decisional conflict regarding LTP-HRT after being presented with the evidence of benefits and risks and clarifying values; (2) to describe the difference between those who accept or decline LTP-HRT in terms of: (a) expectations of LTP-HRT benefits and risks, and (b) the importance women attach to the benefits and the risks; and (3) to describe the factors women identify as contributing to their decision to take or not take LTP-HRT or being unsure about taking LTP-HRT. The typical woman who participated in the study was 57 years of age; had some post secondary education; and was currently using HRT. Over half the women had at least one CHD risk factor and had a hysterectomy. Less than 15% of the respondents reported having osteoporosis or a first degree relative with breast cancer. Women's decisions to take LTP-HRT were distributed as follows: 56% yes; 26% no; and 18% unsure. Women who accepted or declined LTP-HRT did not have statistically significant differences in expectations of risk of CHD, osteoporosis, and breast cancer with and without hormone therapy. In contrast, women's importance ratings of LTP-HRT benefits and side effects did differ significantly between those accepting and declining LTP-HRT. The reasons most often identified by women who chose LTP-HRT were prevention of CHD and osteoporosis (61%) and relief of hot flashes (54%). Those who chose not to take LTP-HRT gave reasons such as dislike of taking pills (47%), and risk of cancer (11%). (Abstract shortened by UMI.)
31
Elinson, Lynn. "Implementation of practice guidelines, a case study of hormone replacement therapy." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp03/NQ27640.pdf.
Full text
32
Cheffins, Tracy. "Hormone replacement therapy and breast cancer in a mammographic screening program /." Title page, table of contents and abstract only, 1997. http://web4.library.adelaide.edu.au/theses/09MPM/09mpmc515.pdf.
Full text
33
Gooding, Kim Mary. "Sex hormones and the microcirculation." Thesis, University of Exeter, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248164.
Full text
34
Yeung, Wing-kwan Rosa. "Adjunctive effect on hormone replacement therapy on periodontal treatment responses in postmenopausal women." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B3765195X.
Full text
35
Jackson, Simon. "Oestrogen supplementation in postmenopausal urinary stress incontinence : effect secondary to altered collagen pathophysiology?" Thesis, University of Bristol, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.390374.
Full text
36
Salagame, Usha Ganesh. "Bisphosphonates, Menopausal Hormone Therapy and Risk Factors for Breast Cancer in Australia." Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/16527.
Full textAbstract:
In Australian women, breast cancer is the second most commonly diagnosed cancer after non-melanoma skin cancers. The use of Menopausal Hormone Therapy (MHT) is an important breast cancer risk factor in postmenopausal women. Prior to findings from large-scale studies on the benefits and harms of MHT, it was used widely, and often, for the management of chronic conditions attributed to menopause, along with its primary use for menopausal symptoms. However, following the availability of such evidence from the Women’s Health Initiative (WHI) trial and other studies in 2002-2003, recommendations for MHT use became more specific and a substantial drop in MHT prescribing was noted in many settings. Although MHT use in Australia dropped substantially after 2002, a significant proportion of women continue to use MHT. Quantifying the breast cancer risks associated with this potentially modifiable risk factor using contemporaneous data in Australian women constitutes an important part of this thesis. Furthermore, a number of other reproductive and lifestyle factors have been found to be associated with breast cancer risk, but these may have differing associations with breast cancer in pre- and postmenopausal women. As an important background to the assessment of MHTassociated risk, these other risk factor associations were quantified in Australian women. Menopause accelerates age-related bone loss which often leads to osteoporosis. Although MHT prevents fracture, because of its generally unfavourable risk profile, when used long-term, it is not recommended first-line for prevention or management of osteoporosis. Bisphosphonates (a class of anti-bone resorptive drugs) are the recommended first-line therapy for osteoporosis. Concurrent with the drop in MHT use after 2002, a substantial increase in bisphosphonate prescribing was noted in many settings. These data raised the possibility that bisphosphonates were replacing MHT, probably as an indirect effect of the WHI trial findings and subsequent revisions to recommendations which restricted its use primarily for short-term menopausal symptom relief. However, among postmenopausal women, evidence-based guidelines and health technology assessments suggest somewhat different target age groups for these two groups of medications. MHT is recommended for relief from vasomotor symptoms around the time of menopause, whereas bisphosphonate use is recommended to women who are at a significant risk of osteoporosis-related fractures, which usually occur a couple of decades after menopause. This thesis examines changes in MHT and bisphosphonate prescribing, in postmenopausal Australian women and a comparable group of women from Manitoba, Canada. The main aims of this thesis are to 1) quantify the relationship between reproductive and lifestyle factors, and breast cancer risk in pre- and postmenopausal Australian women, 2) quantify breast cancer risks associated with MHT use, and to test for this association for specific subtypes of breast cancer, in postmenopausal Australian women and 3) investigate changes in prescribing of MHT and bisphosphonates in women over the age of 50 from Australia and Manitoba, Canada, in relation to the age of the users and the recommendations for use in both settings, over the period 1996-2008. To address Aims 1 and 2, a review of the literature was performed to inform multivariable breast cancer risk factor analyses, which were carried out separately in premenopausal (523 cases/176 controls) and postmenopausal (1276 cases/865 controls) Australian women. Odds ratios for breast cancer associated with MHT use and other risk factors were obtained through multivariable regression analyses using data from an all cancer case-spouse control study-The NSW Cancer Lifestyle and EvAluation of Risk (CLEAR) study. Pathology data on hormone and epidermal growth factor receptor status for a subset of the breast cancer cases (n= 419) was obtained and used to estimate MHTassociated risks for specific breast cancer subtypes. For Aim 3, overall and age-specific MHT and bisphosphonate prescribing patterns in women aged ≥ 50 years, from Australia and Manitoba, Canada were described. In premenopausal women, increased age and family history of breast cancer were found to be associated with increased breast cancer risk, whereas breastfeeding was associated with a reduction in risk. Although limited by sample size, my findings for other factors were generally compatible with the literature. In postmenopausal women, reproductive factors such as nulliparity and increased age at first birth, and increased BMI were found to be associated with increased breast cancer risk. Current use of MHT was found to be associated with a doubling of breast cancer risk; risks were generally higher in users of oestrogen-progestagen combination therapy compared to oestrogen-only MHT, although heterogeneity by type of preparation was not evident. MHT use was associated specifically with an increased risk of developing oestrogen- and progesterone- receptor - positive breast cancers, consistent with the hypothesis that the hormone effects are receptor-mediated. The analyses using ecological data on dispensed medications confirmed that concurrent and substantial drops in MHT prescribing and increases in bisphosphonate prescribing occurred in Australia and Manitoba, Canada, but they occurred in different age-groups of postmenopausal women, in both settings. The drop in MHT prescribing which occurred in women in their fifties and sixties is in agreement with the post-2002 recommendations for more specific and targeted use. The increase in bisphosphonate prescribing in women in their seventies and eighties suggest that their use was generally consistent with recommendations, during the time period studied. A total of 13% of Australian women aged 50-69 currently use MHT with ~75% of them using MHT for ≥ 5 years. The MHT-associated risks estimated in this study provide important information to Australian women and provide additional support to the current guidance by regulatory authorities which recommend that MHT use should be limited to the shortest time possible, in women with moderate to severe menopausal symptoms, who are aware of the risks and benefits.
37
Rhoads, Misty Lynn. "Hormone replacement therapy : attitudes, knowledge, and usage by perimenopausal and postmenopausal women /." View online, 2005. http://repository.eiu.edu/theses/docs/32211131275302.pdf.
Full text
38
Kirsh, Victoria Amy. "Hormone replacement therapy and the risk of breast cancer in postmenopausal women." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape9/PQDD_0004/MQ45912.pdf.
Full text
39
Hosain, Yasmin A. "Class inequalities in prescription drug use, the case of hormone replacement therapy." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2001. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp04/MQ62756.pdf.
Full text
40
Conner, Peter. "Hormone therapy and the breast : aspects on proliferation, apoptosis and mammographic density /." Stockholm : Karolinska institutet, 2004. http://diss.kib.ki.se/2004/91-7349-918-8/.
Full text
41
Morrison, Michael. "Beyond therapy? : investigating biomedical enhancement in the case of human growth hormone." Thesis, University of Nottingham, 2008. http://eprints.nottingham.ac.uk/10631/.
Full textAbstract:
This project is an investigation of the issue of human biomedical enhancement, taking human growth hormone as a case study. Growth hormone is mainly used to increase the adult height of short children, and is also employed illicitly as an anti-ageing treatment. Both these applications are viewed by bioethicists as going beyond the scope of therapeutic medicine by enhancing normal human traits rather than treating diseases and as such are considered ethically suspect. This project adopts a comparative and retrospective stance, examining the socio-historical development of human growth hormone in the US, where much of the impetus for enhancement uses has originated, and also in the UK where the potential for enhancement uses of pharmaceuticals and other medical technologies is a growing concern. This project combines a social constructivist approach to bodies and disease categories with science and technology studies theory on the emergence and shaping of new (medical) technologies. Research focuses on the development of growth hormone as a medical technology and the construction of the diagnostic categories that define the illness it is employed to treat. A combination of archive material and contemporary interview data is used to investigate and identify factors that shape the way some applications of hGH have come to be viewed as legitimate, accepted practices while others remain unstable and controversial. Enhancement suggests an inappropriate use of biomedicine, but in the case of growth hormone at least, the determination of medical need and entitlement is shown to be more than a matter of instrumental measurements. It is a contingent and socially shaped procedure that is applied in heterogeneous ways at different sites in the networks of healthcare provision. This technique provides a different model for thinking about those biomedical practices labelled as enhancement, which does not share the limitations of that framing.
42
Alam, Farhana, Peter D. Semonche, and Dana Reed-Kane. "Patient Satisfaction with Pharmacist Intern Intervention and Consultation in Hormone Replacement Therapy." The University of Arizona, 2016. http://hdl.handle.net/10150/614016.
Full textAbstract:
Class of 2016 AbstractObjectives: Specific Aim #1: Assess no difference in patient satisfaction. Our working hypothesis is that there is no difference in satisfaction with follow-up calls in women receiving HRT from pharmacists or pharmacy intern students at Reed’s Compounding Pharmacy. Specific Aim #2: Assess patient satisfaction with follow-up calls from pharmacy student interns. Our working hypothesis is that women receiving HRT are satisfied with follow-up calls for their therapy when it is conducted by pharmacy student interns, which enhances proper treatment guidance and adherence. Methods: This study will be a descriptive, direct comparison study that will use data obtained through an online questionnaire consisting of the following: four questions determining the patient’s demographics and eighteen questions on patient satisfaction with follow-up calls from Reed’s Compounding Pharmacy with pharmacy student interns. Results: Of the estimated 60 patients sample size, only 31 questionnaires were completed. The largest proportion of patients was between the ages of 51 and 60 (58%). The length of therapy in participating women varied quite significantly with one-fourth of patients on HRT for 4-5 years or more (26%). The patient satisfaction of follow-up calls conducted by pharmacy intern students survey results indicated, in general, that patients agreed that they were satisfied with the service that they were receiving from the pharmacy interns. There was no disagreement with the items, the intern provides education that will help me understand how to take my medications, being pleased that the intern is following-up, having input on hormone therapy, and with the items regarding intern professionalism and intern knowledge. The greatest disagreement was with three items asking about comfort talking with either a female or male intern, and the item about paying extra to ensure follow-up calls. Results from this study were compared with results from five questions adapted using a questionnaire from DiMaggio et al. Note that this study used 7 response fields: strongly disagreed, somewhat disagreed, disagreed, no opinion, agreed, somewhat agreed, strongly agreed. Data from DiMaggio et al used 5 response fields: strongly disagreed, disagreed, no opinion, agreed, strongly agreed. Responses were grouped by strongly disagreed, somewhat disagreed, disagreed, and no opinion in one and strongly agreed, somewhat agreed, and agreed in the second. The data from both studies were compared by considering proportion of patients who agreed at some level with each item. There was no statistical difference between the two groups (p > 0.08); both groups showed a high level of agreement on the five satisfaction items. Conclusions: The women receiving hormone replacement therapy in this study were satisfied with follow-up calls from pharmacy student interns at Reed’s Compounding Pharmacy. There is no difference in satisfaction with follow-up calls in women receiving HRT from pharmacists or pharmacy student interns. In addition to satisfaction, women are satisfied with follow-up calls for their therapy when it is conducted by pharmacy student interns, which enhances proper treatment guidance and adherence.
43
Hill, Deirdre A. "Hormone use patterns, intrauterine device use, and endometrial cancer /." Thesis, Connect to this title online; UW restricted, 1997. http://hdl.handle.net/1773/10899.
Full text
44
Neville, Kristen Ann Women's & Children's Health Faculty of Medicine UNSW. "Hyponatraemia and ADH secretion during intravenous fluid therapy in children." Awarded by:University of New South Wales. Women's & Children's Health, 2009. http://handle.unsw.edu.au/1959.4/44531.
Full textAbstract:
Antidiuretic hormone (ADH) is a fundamental regulator of fluid and electrolyte homeostasis. Osmotically unregulated ADH secretion during intravenous fluid therapy has been implicated in the development of iatrogenic hyponatraemia. The case report and 3 prospective studies of this thesis provide evidence for this and examine the relative contributions of salinity versus infusion rate of intravenous fluids to the development of hyponatraemia. Two studies of plasma and urinary electrolytes and osmolality during intravenous rehydration of children with gastroenteritis were performed. The first, an observational study of 52 children receiving 0.45% (N/2) saline documented persistently raised plasma ADH concentrations independent of plasma sodium. In both studies, plasma and urinary biochemistry suggested osmotically unregulated ADH action. When N/2 and NS were compared in a randomised study of 102 children, NS emerged as superior in the prevention and correction of hyponatraemia, independent of infusion rate. In the third study, 124 pre-operative children were randomised to receive N/2 or NS intravenously at 100% or 50% of maintenance rates post-operatively. Plasma ADH concentrations increased in all groups, and the plasma and urinary biochemistry indicated persistent non-osmotic ADH activity in some children for up to 24 hours. Baseline urinary tonicity approximated NS. Comparison of urinary tonicity with the infused fluid largely explained changes observed in plasma sodium. The risk of hyponatraemia was decreased by isotonic saline but not fluid restriction; however plasma sodium concentration decreased in the NS 100% group between 8 and 24 hours, suggesting that a decreased rate should be considered during prolonged intravenous fluid administration. Fourteen (23%; 7NS) of those on 50% maintenance were assessed as dehydrated, with hypernatraemia in 3 receiving NS50%. The chloride load associated with NS in the second and third studies was not associated with the development of acidosis. The studies also showed that 2.5% dextrose resolved and prevented hypoglycaemia in children with gastroenteritis but was inadequate to prevent hypoglycaemia and/or ketosis in 38% of children under 6 years when infused at maintenance rates. Non-osmotically regulated ADH activity in hospitalised children is common, in the face of which, isotonic is superior to hypotonic saline in decreasing the risk of hyponatraemia.
45
Martins, Marcelo Antonio Domingos [UNESP]. "Qualidade de vida em mulheres na pós-menopausa usuárias e não usuárias da terapia hormonal em unidade básica de saúde de Franca-SP." Universidade Estadual Paulista (UNESP), 2009. http://hdl.handle.net/11449/99260.
Full textAbstract:
Made available in DSpace on 2014-06-11T19:29:52Z (GMT). No. of bitstreams: 0
Previous issue date: 2009-02-18Bitstream added on 2014-06-13T18:39:58Z : No. of bitstreams: 1
martins_mad_me_botfm.pdf: 354151 bytes, checksum: fd9ef52802847e9f7bceaa3e8157d4f3 (MD5)O objetivo desta pesquisa foi avaliar a qualidade de vida de mulheres na pós-menopausa usuárias e não usuárias de terapia hormonal (TH) em Unidade Básica de Saúde (UBS) de Franca-SP. Foi conduzido estudo clínico transversal, com amostra de conveniência composta por 250 mulheres na pós-menopausa, idade entre 45 a 70 anos, atendidas em UBS de setembro de 2007 a agosto de 2008. As participantes foram divididas em dois grupos: usuárias de terapia hormonal (n=70) e não usuárias (controle, n=180). Foram excluídas aquelas com: doenças psiquiátricas, tireopatias não-controladas, doenças malignas, uso de antidepressivos, obesidade grau III, drogaditas e etilistas. Consideraram-se como usuárias de TH aquelas que faziam uso contínuo dessa terapia há pelo menos seis meses. Foram avaliadas as características sócio-demográficas e clínicas. Aplicou-se o Índice Menopausal de Blatt-Kupperman (IMBK) para avaliar a intensidade dos sintomas climatéricos e o Questionário de Saúde da Mulher (QSM) para a avaliação da qualidade de vida. A análise estatística foi realizada pelo teste do Qui-Quadrado ou exato de Fisher, teste de Mann-Whitney ou de Kruskal-Wallis. Os resultados não mostraram diferenças significativas na comparação entre os grupos quanto à idade, menarca, menopausa, paridade e índice massa corpórea. Observou-se que 67,2% eram casadas (168/250), 83,2% com ensino fundamental (208/250) e 53,2% se ocupavam com os trabalhos domésticos (133/250), não diferindo entre os grupos. As usuárias de TH relataram menor freqüência de sintomas climatéricos (IMBK) de intensidade moderada e acentuada, comparadas a não usuárias (p<0,001). Na avaliação do QSM, verificou-se entre as usuárias de TH, menor escore médio quanto ao déficit cognitivo (p<0,001), sintomas...
This research aims at assessing the quality of life in postmenopausal women who were users and non-users of hormone therapy (HT) in public health care unit (HCU) of Franca- SP. This cross-sectional, clinical study was undertaken in a convenience sample consisting of 250 postmenopausal women, aged 45-70 years, followed up at the HCU from September 2007 to August 2008. The patients were divided in two groups: users of HT (n=70) and non-users of HT (control, n=180). Exclusion criteria: obesity, psychiatric disturbances, antidepressants use, uncontrolled thyroid diseases, drug addicts, alcohol addicts and malignant diseases carriers. Women considered HT users were those who had undergone this treatment for at least six months. Socio-demographics and clinical characteristics were assessed. The Blatt-Kupperman Menopausal Index (BKMI) was applied to rate the intensity of climacteric symptoms and the Women’s Health Questionnaire (WHQ) was applied to assess women’s quality of life. For data statistical analysis, a Qui-square tests, a Fisher’s Exact Test, a Mann-Whitney Test and Kruskal- Wallis test were used. The results show that there is no significant difference between groups regarding age, menarche, menopause, parity and body mass index. At total 67.2% of women were married (168/250), 83.2% had received fundamental education (208/250) and 53.2% were busy with house chores (133/250), not differing among the group. HT users reported a lower frequency of moderate and severe climacteric symptoms (p<0.001). From WHQ, it was observed among the HT users lower average score of memory concentration (p<0.001), vasomotor symptoms (p=0.048), sleep problems (p<0.001) and attractiveness (p=0.024); however there were no differences between groups regarding the QSM total score. In conclusion, postmenopausal women who were users and nonusers of HT, followed up at a health care unit, not presented differences in global quality of life.
46
Pace, Diane Todd. "Effect of postmenopausal hormone replacement on heart rate variability." View the abstract Download the full-text PDF version, 1998. http://etd.utmem.edu/ABSTRACTS/1998-003-pace-index.html.
Full textAbstract:
Thesis (Ph.D)--University of Tennessee Health Science Center, 1998.Title from title page screen (viewed on October 17 2008). Research advisor: Kay F. Engelhardt. Document formatted into pages (xi, 162 p. : ill.). Vita. Abstract. Includes bibliographical references (p.162).
47
Yeung, Wing-kwan Rosa, and 楊穎筠. "Adjunctive effect on hormone replacement therapy on periodontal treatment responses in postmenopausal women." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B3765195X.
Full text
48
Bakr, Mahmoud. "Parathyroid hormone effect on facilitating stress fracture repair." Thesis, Griffith University, 2019. http://hdl.handle.net/10072/389571.
Full textAbstract:
Stress fractures (SFx) result from repetitive cyclical loading of bone. They are frequent athletic injuries and underlie atypical femoral fractures following long-term bisphosphonate (BP) therapy. Parathyroid hormone (PTH) and BPs, including Alendronate (ALN), have opposing effects on bone dynamics. ALN is an antiresorptive agent that decreases bone turnover, and with prolonged doses of BP the healing of SFxs is delayed. The extent to which intermittent PTH (iPTH) remains effective in the treatment of SFx in the presence of an ongoing BP treatment has not been tested. Starting 24 hours after SFx induction, the effect of a single PTH injection, and daily iPTH injections for 14 days, on the healing of SFx in the rat ulna was investigated. SFx was induced in 330 female Wistar rats (300 +- 15 g) during a single loading session. In the single PTH injection experiment, rats were divided into two groups (n=60). A single PTH (8 μg/100g) or vehicle (VEH) saline injection was administered 24 hours after loading. Ulnae were examined 1, 2, 6 or 10 weeks following SFx.Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Medical Science
Griffith Health
Full Text
49
McKenzie, Joyce. "Effects of hormone replacement therapy on postmenopausal women with type 2 diabetes mellitus." Thesis, University of Glasgow, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.433922.
Full text
50
Talbi, Oussama. "Synthesis of Homo A-CD Estrogens for Potential Use in Hormone Replacement Therapy." Thesis, Université d'Ottawa / University of Ottawa, 2015. http://hdl.handle.net/10393/32082.
Full textAbstract:
Hormone replacement therapy (HRT) has been subject to much debate due to concerns that long term use of such treatment of menopause increases the risk of breast and uterine cancer. This is thought to be caused by estradiol (1) binding to the estrogen receptor α (ERα) resulting in increased cell proliferation. Another possible mechanism relates to toxicity of the estrodiol metabolites, which are thought to be genotoxic ortho-quinones. In a previous project, a series of A-CD estrogens (2) were synthesised as non-carcinogenic estradiol agonists where the cis CD ring junction was thought to be the cause of the desirable selectivity for ERβ. In this thesis, homo A-CDs were synthesised (3) with expansion of the D ring thought to increase the selecitivty for ERβ. Relative Binding Affinities (RBA) were determined with selectivity to ERα and ERβ. Most ligands showed decreased selectivity when compared to the original A-CD series. However, compounds carrying the CF3 moiety continued to show very high potency. In addition, novel synthetic routes were employed in the preparation of certain compounds.